Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · S

S. 3822 (109th)

Genomics and Personalized Medicine Act of 2006

referredUnited States· United States Congress· EN

Introduced

3 August 2006

Last action

3 August 2006 · Introduced

Status

Read twice and referred to the Committee on Finance.

Sponsors

Sen. Obama, Barack [D-IL]

Subjects

Healthcare, Environment, Taxation

Source updated

15 August 2025

Healthcare · Environment · Taxation

Summary

Genomics and Personalized Medicine Act of 2006 - Requires the Secretary of Health and Human Services to: (1) establish the Genomics and Personalized Medicine Interagency Working Group to expand and accelerate genetics and genomics research and translate such research into clinical and public health applications; (2) expand and accelerate research and programs to collect genetic and genomic data that will advance the field of genomics and personalized medicine; (3) develop a plan for a national biobanking research initiative; (4) expand efforts to increase knowledge about the interaction between genetics and the environment and about ways in which molecular genetic screening, diagnostics, and treatments may be used to improve the health and health care of racial and ethnic minority populations; (5) increase recruitment and retention of trainees in genetics and genomics; (6) ensure the adequacy of genetics and genomics training for diagnosis, treatment, and counseling of adults and children for both rare and common disorders; (7) improve the safety, efficacy, and availability of information about genetic tests; and (8) improve the oversight and regulation of genetic tests. Provides for the recruitment of health professionals from diverse backgrounds in the genomics workforce and improvement in the quality of genomics training. Amends the Internal Revenue Code to establish a tax credit for qualified research expenses for the development of a qualified companion diagnostic test designed to provide information to increase the safety or effectiveness of a drug. Provides for the expansion of adverse event reporting systems to encompass reports of adverse events resulting from genetic testing.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 3 August 2006

    Introduced

    Read twice and referred to the Committee on Finance.

    Source: IntroReferral

  2. 3 August 2006

    Introduced

    Sponsor introductory remarks on measure. (CR S8840-8841)

    Source: IntroReferral

  3. 3 August 2006

    Introduced

    Introduced in Senate

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in Senate (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate (text)

    Introduced in Senate · EN · 3 August 2006

    ViewDownloadOpen at official source

  • Introduced in Senate (PDF)

    Introduced in Senate · EN · 3 August 2006

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate

    summary · EN · 3 August 2006

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.